<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00892268</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000629150</org_study_id>
    <secondary_id>P30CA023074</secondary_id>
    <secondary_id>UARIZ-07-0792-04</secondary_id>
    <secondary_id>IRUSANAS0084</secondary_id>
    <nct_id>NCT00892268</nct_id>
  </id_info>
  <brief_title>Acupuncture or Medication in Reducing Pain in Postmenopausal Women With Breast Cancer and Joint Pain</brief_title>
  <official_title>Acupuncture for the Treatment of Aromatase Inhibitor Associated Joint Pain in Post-Menopausal Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Acupuncture may reduce joint pain in postmenopausal women with breast cancer. It&#xD;
      is not yet known whether acupuncture is more effective than standard therapy analgesics in&#xD;
      decreasing joint pain caused by aromatase inhibitors.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying acupuncture to see how well it works&#xD;
      compared with medication in reducing pain in postmenopausal women with breast cancer and&#xD;
      joint pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate the efficacy of acupuncture in reducing pain, defined by improvements in&#xD;
           overall WOMAC score at 6 weeks, in post-menopausal women with breast cancer and&#xD;
           aromatase inhibitor (AI)-associated arthralgia.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To identify biologic correlates to acupuncture efficacy in this specific syndrome of&#xD;
           AI-associated pain.&#xD;
&#xD;
        -  To evaluate the efficacy of acupuncture in these patients.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms:&#xD;
&#xD;
        -  Arm I: Patients undergo acupuncture for 20-30 minutes, on the appropriate pain points on&#xD;
           the anterior portion of the body alternating with posterior portion of the body, thrice&#xD;
           weekly for 2 weeks and then twice weekly for 3 weeks.&#xD;
&#xD;
        -  Arm II: Patients receive standard-of-care analgesics (i.e., NSAIDs, narcotics,&#xD;
           acetaminophen, or other) for 5 weeks. Patients not responding to analgesia may cross&#xD;
           over to arm I.&#xD;
&#xD;
      Patients are assessed periodically for improvement in pain, menopausal symptoms, and overall&#xD;
      quality of life by the WOMAC, Brief Pain Inventory, and FACT-ES questionnaires.&#xD;
&#xD;
      Blood samples are collected at baseline, 6 weeks, 3 months, and 6 months for biomarker&#xD;
      studies of brain-derived neurotrophic factor and serotonin-transporter gene polymorphisms&#xD;
      levels by ELISA.&#xD;
&#xD;
      After completion of study therapy, patients are followed at 1 week, 6 weeks, 3 months, and 6&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accural&#xD;
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in pain, as defined by the WOMAC global score at 6 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acupuncture efficacy as defined by bio-correlates, e.g., changes in BDNF and STGP levels</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menopausal symptoms as defined by the FACT-ES</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Menopausal Symptoms</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo acupuncture for 20-30 minutes, on the appropriate pain points on the anterior portion of the body alternating with posterior portion of the body, thrice weekly for 2 weeks and then twice weekly for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive standard-of-care analgesics (i.e., NSAIDs, narcotics, acetaminophen, or other) for 5 weeks. Patients not responding to analgesia may cross over to arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>acupuncture therapy</intervention_name>
    <description>Undergo acupuncture</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pain therapy</intervention_name>
    <description>Receive standard care</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of breast cancer&#xD;
&#xD;
          -  Concurrent therapy with anastrozole for the adjuvant treatment of breast cancer&#xD;
&#xD;
          -  Must have moderate or worse arthralgia, as defined by a baseline WOMAC pain scale&#xD;
             score ≥ 48&#xD;
&#xD;
               -  Patients with other underlying pain syndromes (e.g., osteoarthritis) are&#xD;
                  eligible, but the arthralgia must have worsened since starting anastrozole&#xD;
&#xD;
          -  Hormone receptor-positive disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Post-menopausal status meeting the following criteria:&#xD;
&#xD;
               -  At least 12 months without spontaneous menstrual bleeding&#xD;
&#xD;
               -  History of bilateral salpingo-oophorectomy with or without hysterectomy&#xD;
&#xD;
               -  Age &gt; 55 with hysterectomy with or without oophorectomy&#xD;
&#xD;
               -  Age &lt; 55 with hysterectomy without oophorectomy or with unknown status, and serum&#xD;
                  FSH in post-menopausal range within the past 4 weeks&#xD;
&#xD;
          -  Not needle phobic&#xD;
&#xD;
          -  Patients with a contraindication to NSAIDs (i.e., prior gastrointestinal bleed&#xD;
             secondary to NSAIDs or severe renal insufficiency) are eligible, but will be treated&#xD;
             with alternative analgesics such as narcotics or acetaminophen&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Concurrent chronic narcotics or NSAIDs allowed, but doses must be stable for ≥ the&#xD;
             past month&#xD;
&#xD;
          -  Concurrent antidepressant medications allowed, but doses must be stable for ≥ the past&#xD;
             3 months&#xD;
&#xD;
          -  At least 6 months since prior acupuncture&#xD;
&#xD;
          -  No prior acupuncture for aromatase inhibitor-associated pain syndrome&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leona B. Downey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>May 1, 2009</study_first_submitted>
  <study_first_submitted_qc>May 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2009</study_first_posted>
  <last_update_submitted>April 23, 2010</last_update_submitted>
  <last_update_submitted_qc>April 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Leona B. Downey</name_title>
    <organization>Arizona Cancer Center at University of Arizona Health Sciences Center</organization>
  </responsible_party>
  <keyword>menopausal symptoms</keyword>
  <keyword>estrogen receptor-positive breast cancer</keyword>
  <keyword>progesterone receptor-positive breast cancer</keyword>
  <keyword>breast cancer</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Arthralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

